enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Regeneron preliminary Q4 US sales of Eylea below expectations

   www.aol.com/news/regeneron-preliminary-q4-us...

   Eylea, jointly developed with Bayer AG, has driven Regeneron's earnings for years, but sales have now come under pressure, partly from Roche's Vabysmo that secured U.S. approval in 2022. Regeneron ...

3. Regeneron beats quarterly results on strong demand for ... - AOL

   www.aol.com/news/regeneron-beats-quarterly...

   U.S. sales of Eylea, jointly developed with Bayer AG, rose 2% to $1.53 billion in the reported quarter from a year earlier, above LSEG estimates of $1.47 billion. ... Vabysmo, and raised its full ...

4. US FDA declines to approve Regeneron's higher-dose Eylea ...

   www.aol.com/news/us-fda-declines-approve...

   Eylea, which recorded $9.65 billion in global sales last year, has been hit since Roche's rival treatment Vabysmo was approved last year for wet age-related macular degeneration (AMD) and diabetic ...

5. Faricimab - Wikipedia

   en.wikipedia.org/wiki/Faricimab

   Faricimab, sold under the brand name Vabysmo (/ v ə ˈ b aɪ z m oʊ / və-BYEZ-mow), is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).

6. Macular edema - Wikipedia

   en.wikipedia.org/wiki/Macular_edema

   On July 29, 2014, Eylea (aflibercept), an intravitreal injection produced by Regeneron Pharmaceuticals Inc., was approved to treat DME in the United States. [17] On January 28, 2022, Vabysmo, a different injectable eye medication produced by Genentech was approved to treat both Wet AMD and DME in the United States. [18]

7. Aflibercept - Wikipedia

   en.wikipedia.org/wiki/Aflibercept

   Aflibercept, sold under the brand names Eylea and Zaltrap among others, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. [ 16 ] [ 17 ] It was developed by Regeneron Pharmaceuticals .

8. Regeneron's Eylea could return to growth after nod to high ...

   www.aol.com/news/regenerons-eylea-could-return...

   A longer dosing gap for the drug could help Regeneron take on rival Roche's Vabysmo and also help soften the blow from incoming cheaper copycat drugs, analysts said. Shares of Regeneron rose 1.7% ...

9. US FDA approves two biosimilars for blockbuster eye drug Eylea

   www.aol.com/news/us-fda-approves-two-biosimilars...

   (Reuters) -The U.S. Food and Drug Administration (FDA) on Monday approved two close copies of Regeneron Pharmaceuticals' Eylea, its first-ever clearance to biosimilar versions of the blockbuster ...